• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.

作者信息

Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeyer G, Heit W, Hossfeld D, Weh H, Ludwig W D, Thiel E

机构信息

Department of Medicine, University of Münster, Germany.

出版信息

Semin Hematol. 1991 Jul;28(3 Suppl 4):76-9.

PMID:1780757
Abstract
摘要

相似文献

1
Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group.急性髓系白血病患者采用极早期强化联合延长维持化疗提高治愈率：来自急性髓系白血病协作组的数据
Semin Hematol. 1991 Jul;28(3 Suppl 4):76-9.
2
Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.急性髓系白血病（AML）首次缓解期强化巩固化疗与标准巩固维持治疗的比较。一项欧洲癌症研究与治疗组织（EORTC）/意大利成人白血病研究组（GIMEMA）的III期试验（AML8 B）。EORTC白血病协作组和GIMEMA组
Leukemia. 1992;6 Suppl 2:76-7.
3
The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).早期强化治疗对急性髓系白血病（AML）患儿无事件生存期（EFS）的影响。
Leukemia. 1992;6 Suppl 2:52-4.
4
Remission induction therapy: the more intensive the better?缓解诱导疗法：强度越高越好？
Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S41-4. doi: 10.1007/s002800100305.
5
SAB--a promising new treatment to improve remission rates in AML in the elderly?SAB——一种有望提高老年急性髓系白血病缓解率的新疗法？
Br J Haematol. 2002 Aug;118(2):432-3. doi: 10.1046/j.1365-2141.2002.03620.x.
6
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG.急性髓系白血病长期维持治疗及极早期强化化疗的长期影响：来自德国急性髓系白血病协作组（AMLCG）的数据
Leukemia. 1992;6 Suppl 2:68-71.
7
Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.依托泊苷、6-硫鸟嘌呤和伊达比星（ETI）口服诱导及巩固治疗老年急性髓系白血病：与5天TAD方案的随机对照研究。芬兰白血病研究组
Leukemia. 1994 Jan;8(1):11-5.
8
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.米托蒽醌与柔红霉素用于诱导巩固化疗——小剂量阿糖胞苷对维持缓解的价值以及老年急性髓系白血病预后因素评估：最终报告。欧洲癌症研究与治疗组织及荷兰 - 比利时血液肿瘤协作组霍冯小组
J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872.
9
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.6-硫鸟嘌呤、阿糖胞苷和柔红霉素（TAD）以及高剂量阿糖胞苷和米托蒽醌（HAM）用于诱导治疗，TAD用于巩固治疗，对于各年龄段初发急性髓系白血病（AML）的成年患者，采用每月减量的TAD进行长期维持治疗或TAD-HAM-TAD方案，以及通过序贯HAM进行一个疗程的强化巩固治疗：德国AML协作组的一项随机试验
J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133.
10
Comparison of survival. Chemotherapeutically treated and untreated older patient with acute myeloid leukemia.生存情况比较。接受化疗与未接受化疗的老年急性髓系白血病患者。
J Fla Med Assoc. 1994 Jul;81(7):475-7.

引用本文的文献

1
Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.英国急性髓系白血病患者使用非格司亭的经济学分析：资源使用数据收集方法的比较
Pharmacoeconomics. 2002;20(10):665-74. doi: 10.2165/00019053-200220100-00003.